EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani iD, Hun Ju Lee iD, Nathalie A Johnson, Pauline Brice, John Radford iD, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow iD, Margaret A Shipp iD und 6 weitere

Blood · 07.09.2023 · 142 (10) · 878-886

DOI: 10.1182/blood.2022019386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 07.09.2023. Verfasst von Philippe Armand und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hodgkin Disease. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV; cohort 1), salvage chemotherapy and BV without ASCT (cohort 2), or ASCT without subsequent BV (cohort 3), received pembrolizumab for ≤2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were the objective response rate (ORR) using blinded central review and safety. The median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained a response for ≥4 years. Median overall survival was not achieved. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients; no treatment-related deaths occurred. Single-agent pembrolizumab can induce durable responses, particularly in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHodgkin DiseaseHumansFollow-Up StudiesNeoplasm Recurrence, LocalTransplantation, AutologousClinical Trials, Phase II as TopicAntibodies, Monoclonal, Humanized

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
  • Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Medicine, Jewish General Hospital, Montreal, QC, Canada.
  • Hémato-Oncologie, Hôpital Saint-Louis, Paris, France.

ORCID-Profile: Pier Luigi Zinzani, Hun Ju Lee, John Radford, Bastian von Tresckow, Margaret A Shipp, Alex F Herrera

Zitieren

APA

Armand, P., Zinzani, P. L., Lee, H. J., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Herrera, A. F., Lin, J., Kim, E., Chakraborty, S., Marinello, P., & Moskowitz, C. H. (2023). Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood, 142(10), 878-886. https://doi.org/10.1182/blood.2022019386

Vancouver

Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886. doi:10.1182/blood.2022019386

BibTeX
@article{Armand2023,
  author = {Armand, Philippe and Zinzani, Pier Luigi and Lee, Hun Ju and Johnson, Nathalie A and Brice, Pauline and Radford, John and Ribrag, Vincent and Molin, Daniel and Vassilakopoulos, Theodoros P and Tomita, Akihiro and von Tresckow, Bastian and Shipp, Margaret A and Herrera, Alex F and Lin, Jianxin and Kim, Eunhee and Chakraborty, Samhita and Marinello, Patricia and Moskowitz, Craig H},
  title = {Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma},
  journal = {Blood},
  year = {2023},
  volume = {142},
  number = {10},
  pages = {878--886},
  doi = {10.1182/blood.2022019386}
}
Kostenlos starten →